CMC Biologics, IDT Biologika Collaborate
News Feb 27, 2016
CMC Biologics A/S and IDT Biologika GmbH have announced the formation of a strategic collaboration to provide a complete and efficient solution for the manufacture of antibody drug conjugates (ADCs). Within this collaboration, CMC Biologics will perform process development and manufacture of the bulk monoclonal antibody and IDT Biologika will perform services from conjugation of the cytotoxic drug to the antibody substance through to the aseptic fill, finish and packaging of the ADC final drug product.
This joint manufacturing solution will provide speed, reliability, quality ADC manufacturing and a simplified supply chain, from DNA to finished drug product, for clinical trials and beyond through commercial manufacturing. Additional details will be provided at the upcoming DCAT conference in March and initial services will become available to clients in April 2016.
“The collaboration with CMC Biologics is an important step to provide full ADC manufacturing services to meet the needs of ADC development and production in this rapidly growing field,” said Dr. Ralf Pfirmann, Chief Executive Officer of IDT Biologika.
“Our new collaboration permits IDT Biologika to leverage its biologics and cytotoxics capabilities and facilities, and their unique combination in the business, manufacturing and development portfolio at IDT´s Dessau headquarter site, to provide ADC developers with a highly reliable and efficient solution for early process development through clinical and commercial manufacturing based on our capabilities and experience. We see this as an important undertaking to make a meaningful difference in human health.”
“We are delighted to be working with IDT Biologika, one of the fastest growing and innovative CMOs in Germany and now in North America,” said Gustavo Mahler, PhD, Chief Executive Officer of CMC Biologics. “We share the common values with IDT Biologika with a constant focus on manufacturing excellence and a dedication to customer service.”
New evidence published in the Cochrane Library provides high quality evidence that people who use a combination of nicotine replacement therapies (a patch plus a short acting form, such as gum or lozenge) are more likely to successfully quit smoking than people who use a single form of the medicine.READ MORE